Otros idiomas Lunit Inc.

Acciones

A328130

KR7328130000

Precio de cierre Korea S.E. Otros sitios de cotización 00:00:00 04/06/2024			Varia. Cinco días.	Varia. 1 de enero.
54.500 ^KRW	-1,27 %		+3,02 %	-33,46 %

24/05	Lunit presentará 7 estudios en Asco 2024, entre ellos innovaciones en la cuantificación de Her2 y modelos predictivos multimodales de respuesta a la inmunoterapia	CI
13/05	Lunit Inc. (KOSDAQ:A328130) completó la adquisición de Volpara Health Technologies Limited (ASX:VHT) a Harbour Asset Management Limited y otros.	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	24/05
Lunit Acquires New Zealand's Volpara Health Technologies	23/05
Lunit Inc. completed the acquisition of Volpara Health Technologies Limited from Harbour Asset Management Limited and others.	13/05
Volpara to Delist After Court Approves Acquisition by Lunit	03/05
Lunit Wins Shareholder Approval for Volpara Health Takeover	16/04
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover	12/04
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals	08/04
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients	27/03
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO	26/03
Lunit Announces Two Commercial Deals Signal its Expansion in Europe	18/03
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research	15/03
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region	11/03
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings	29/02
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC	19/02
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology	18/01
Lunit Announces Three-Year Supply Contract with Samsung Electronics	16/01
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment	26/12
Lunit to Acquire Volpara, Scheme Implementation Agreement Signed	15/12
Lunit to Take Over Volpara Health; Lunit Shares Decline 4%	15/12
Lunit Inc. agreed to acquire Volpara Health Technologies Limited from Harbour Asset Management Limited and others for AUD 300 million.	13/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Lunit Inc.

Acciones

A328130

KR7328130000

Otros idiomas

Filtros